Literature DB >> 2051979

[Quality of life of patients after esophagectomy for esophageal cancer].

Y Noguchi1, M Baba, S Nakano, T Fukumoto, H Yoshinaka, T Aikou, H Shimazu.   

Abstract

Quality of life of 79 patients who underwent esophagectomy for esophageal cancer and survived more than one year was evaluated by a questionnaire method. About 90% of patients had a good appetite, taking ordinary solid foods, and 69% were satisfied with the daily amount of foods. About 40% of patients complained of passage disturbance on swallowing, abdominal pain or diarrhea after meal. Fifty seven per cent of patients had frequent episodes of cough and sputum, and 20% were not able to go up the stairs to the third floor because of short breath. Thirty two per cent of patients with recurrent nerve paresis and even 5% without paresis had a trouble in daily conversation. These physical distresses were thought to be useful indicators for the doctor to evaluate the quality of life of patients. Additionally, about 30% of patients had a tendency of mental depression postoperatively. Fifty six per cent of patients who had worked before operation returned to work or were doing a lighter work than before. The psychological factor and social rehabilitation were suggested to be very important, when evaluated from the patient's side. Especially in case of aggressive surgery for esophageal cancer, postoperative quality of life of patients should be carefully considered from the viewpoints of both the patient and doctor.

Entities:  

Mesh:

Year:  1991        PMID: 2051979

Source DB:  PubMed          Journal:  Nihon Geka Gakkai Zasshi        ISSN: 0301-4894


  1 in total

1.  Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy.

Authors:  H Fujita; T Kakegawa; H Yamana; I Shima; Y Toh; Y Tomita; T Fujii; K Yamasaki; K Higaki; T Noake
Journal:  Ann Surg       Date:  1995-11       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.